<DOC>
	<DOCNO>NCT01913730</DOCNO>
	<brief_summary>This multicenter , randomize , open label study design evaluate efficacy safety prolong treatment bortezomib twice monthly dexamethasone salvage treatment contain bortezomib relapse refractory multiple myeloma patient .</brief_summary>
	<brief_title>Maintenance Therapy With Subcutaneous Bortezomib</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>1 . Patient legally consent age define local regulation . 2 . Patient , investigator ( ) opinion willing able comply protocol requirement . 3 . Patient give voluntary write informed consent performance studyrelated procedure part normal medical care , understand consent may withdraw patient time without prejudice future medical care . 4 . Female patient either postmenopausal 24 consecutive month surgically sterilise agree continuous abstinence heterosexual sexual contact willing use two acceptable method birth control time ( one highly effective method one additional effective method ) ( Highly Effective Methods : Intrauterine device IUD ; Hormonal birth control pill , injection , implant ; tubal ligation ; partner 's vasectomy ; Additional Effective Methods : Latex condom ; Diaphragm ; Cervical Cap ) 4 week prior begin study drug therapy , study drug therapy ( include dose interruption ) 4 week discontinuation therapy . 5 . Male patient agree use acceptable method contraception ( i.e. , condom abstinence ) study drug therapy ( include dose interruption ) 4 week discontinuation bortezomib therapy . 6 . Patient previously diagnose multiple myeloma base standard criterion . 7 . Patient relapse refractory one three line treatment last one must bortezomibcontaining regimen , without evidence progressive disease . 8 . Patient previously receive least 4 cycle salvage treatment contain bortezomib , enrolment , without evidence progressive disease . 9 . Patient must enrol start therapy within 45 day completion last salvage cycle contain Bortezomib . 10 . Before salvage treatment bortezomibbased regimen , patient must measurable disease 1 . Any serious medical condition , laboratory abnormality psychiatric illness prevent subject signing informed consent form place subject unacceptable risk . 2 . Pregnant lactating female 3 . Known positive HIV active infectious hepatitis type A , B C 4 . Peripheral neuropathy neuropathic pain grade 2 high , defined National Cancer Institute Common Toxicity Criteria ( NCI CTC ) 4.0 5 . Infiltrative pulmonary disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Refractory</keyword>
	<keyword>Relapsed</keyword>
</DOC>